A critical step in the development process for an antibody drug conjugate (ADC) is establishing scientifically sound analytical methods that measure key product quality attributes to support pre-clinical activities and downstream clinical release and stability testing. By leveraging key technologies and platform analytical methods, drug developers can expedite an early-phase biologics’ path to IND by removing analytical method development from the critical path.

Join us on an exploration of the analytical characterization required to confidently assess the ID, safety and efficacy of an antibody drug conjugate (ADC). We will start with a practitioners view on the requisite analytics and then shift to several case studies where multiple techniques, from mass spectrometry to light scattering, were used to interrogate these complex protein conjugates.

This webinar promises a comprehensive look at the analytical processes and technologies needed to successfully advance ADC development.

In this webinar you’ll learn:

• Thermal stability and conformational changes associated with the drug-antibody-ratio (DAR)
• How light scattering can be used to study the aggregation of ADCs
• The precision and detail that mass spectrometry provides for ADC characterization
• Justification of application of platform analytical strategies to IgGs and lessons learned

• Biophysical scientists in government and academia
• Biopharm method development
• Biopharm process development
• Biopharm CMC